April 25th 2025
Adding venetoclax to decitabine-cedazuridine significantly enhanced response rates in patients with higher-risk myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia.
Dupilumab Efficacy in Asthma, AD, EoE, and CRSwNP Not Affected By Eosinophil Count
June 8th 2022Dupilumab-induced increases in mean eosinophil counts were shown to wane over time in patients with asthma, chronic rhinosinusitis with nasal polyps (CRSwNP), and atopic dermatitis (AD), with incidence of eosinophilia not shown to reduce efficacy of the biologic.
Read More
Cardinal Health’s Aklilu Tedla on CAR T-Cell Administration Outside of the Hospital
June 8th 2022Moving chimeric antigen receptor (CAR) T-cell therapies outside of the hospital will bring training and safety challenges, said Aklilu Tedla, vice president, insights and engagement, regulatory science, cell and gene, Cardinal Health.
Watch
Dr Kim A. Reiss: There Are Several Exciting Developments in Pancreatic Cancer Research
June 6th 2022Kim A. Reiss, MD, assistant program director of the Hematology/Oncology Fellowship Program and assistant professor of medicine at the Hospital of the University of Pennsylvania, discusses pancreatic cancer research she presented at the 2022 American Society of Clinical Oncology Annual Meeting.
Watch
Dr Joel W. Neal: Cabozantinib/Atezolizumab May Fullfill Unmet Targeted Treatment Need in NSCLC
June 6th 2022Joel W. Neal, MD, PhD, associate professor, Division of Oncology, Stanford Cancer Institute, is lead investigator on the COSMIC-021 trial, which is investigating cabozantinib plus atezolizumab vs cabozantinib alone in patients with advanced non–small cell lung cancer (NSCLC) as a possible second-line treatment beyond chemotherapy.
Watch
Dr David R. Penberthy: Knowledge Gained at ASCO Can Transform Cancer Care
June 5th 2022David R. Penberthy, MD, MBA, is medical director, Radiation Oncology, Bon Secours-Southside Medical Center in Petersburg, Virginia, and president of the Association of Community Cancer Centers for the 2022-2023 term.
Watch
Study Identifies Predictors of Eosinophilic Disease in CRS With Nasal Polyps
June 4th 2022Asthma history and olfactory, rhinorrhea, and nasal polyp endoscopy scores were identified as independent predictors of eosinophilic disease in Chinese patients with chronic rhinosinusitis with nasal polyps.
Read More
Dr Kashyap Patel Discusses the Importance of WES in Reducing Targeted Treatment Disparities
June 4th 2022Kashyap Patel, MD, CEO of Carolina Blood and Cancer Care Associates, current president of the Community Oncology Alliance, and associate editor of Evidence-Based Oncology™, discusses his partnership with Sema4 and LabCorp and their joint goal to advance whole-exome sequencing (WES) for targeted oncology treatment.
Watch
Long-term Use of Budesonide Nasal Irrigation Effective for Comorbid CRS With Nasal Polyps, Asthma
June 3rd 2022Patients with comorbid chronic rhinosinusitis (CRS) with nasal polyps and asthma reported significant reductions in endoscopic sinus score and severity, as well as decreased dosage of oral steroids and antibiotics after long-term use of budesonide nasal irrigation.
Read More
Contributor: The Case for Education and Clinical Decision Support With Pharmacogenetics
June 2nd 2022Prescribing is a complex process with multiple factors to consider on top of the 3 primary questions about effectiveness, harm, and cost. Pharmacogenetics has put this complexity under the spotlight and prompted educational programs and the development of new clinical decision support systems.
Read More
Dr Randall A. Oyer: Clinical Trials Must Be Accessible to Everyone
June 1st 2022Randall A. Oyer, MD, medical director, oncology, and medical director, Cancer Risk Evaluation Program, Lancaster General Health, and clinical professor of cancer biology at Penn Medicine, discusses the recent American Society of Clinical Oncology/Association of Community Cancer Centers recommendations for improving diversity in clinical trials.
Watch
Dr Kashyap Patel Updates on Exciting Developments at ASCO22
June 1st 2022Kashyap Patel, MD, CEO of Carolina Blood and Cancer Care Associates, current president of the Community Oncology Alliance, and associate editor of Evidence-Based Oncology™, talks with us ahead of the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting.
Watch
Food Sensitization in Early-Onset AD Linked With Later Allergic Respiratory Diseases
May 31st 2022Pediatric patients with early-onset atopic dermatitis (AD) who reported incidence of food sensitization were associated with later allergic respiratory diseases, in which persistence of AD was linked with multiple food allergies.
Read More
FDA Approves Tisa-Cel for Third Indication, R/R Follicular Lymphoma
May 31st 2022Tisagenlecleucel (tisa-cel) was approved to treat adults with relapsed or refractory (R/R) follicular lymphoma. This is the third indication for the therapy since it became the first FDA-approved chimeric antigen receptor T-cell therapy in 2017.
Read More
Cardinal Health’s Aklilu Tedla Discusses Logistics of Allogeneic CAR T-Cell Therapies
May 31st 2022Allogeneic, or off-the-shelf, chimeric antigen receptor (CAR) T-cell therapies will bring new logistical challenges, said Aklilu Tedla, vice president, insights and engagement, regulatory science, cell and gene, Cardinal Health.
Watch
Real-world Efficacy of Risankizumab in Psoriasis Shown for Patients With Prior Biologic Failure
May 28th 2022Real-world patients with moderate to severe plaque psoriasis who had experienced prior biologic failure demonstrated significant improvement and an adequate safety profile with risankizumab treatment.
Read More
California, Kentucky, Oregon, Florida Announce Postpartum Medicaid Expansion
May 26th 2022Thanks to flexibilities provided by the American Rescue Plan, 4 states announced Wednesday they will expand Medicaid coverage to 12 months postpartum, joining others who have already adopted similar measures.
Read More
New Research Calls for a Reconsideration of Loop Diuretic Use, Fluid Restriction in HF
May 25th 2022Thirst outcomes were investigated among patients with stable heart failure (HF), due to the limited data available on this relationship and how it, along with fluid and sodium intake, influences clinical outcomes in this population.
Read More